November 16, 2021
Astellas Pharma and Germany’s Pantherna Therapeutics have sealed a technology evaluation agreement for the research of mRNA-based regenerative medicines, the two companies said on November 15. The collaboration is aimed at capitalizing on Pantherna’s proprietary mRNA platform combined with Astellas’...read more